From China to the Global Stage: magAssist Selected Among Fortune’s 23 Featured Healthcare Companies

Fortune magazine, in collaboration with Well Equity Partners, released its 2025 list of healthcare companies to watch. magAssist (Suzhou) Co., Ltd. was selected alongside Fortune Global 500 companies and emerging innovators, reflecting its innovation capabilities and potential in the global healthcare market.

Heart Failure at the Core of “Health + Longevity”

Heart failure is one of the most critical challenges to achieving the goals of health and longevity. Its high prevalence among aging populations, combined with recurrent hospitalizations and high mortality risk, makes it a central focus of modern healthcare systems.

The healthcare paradigm emphasizes integrated management across acute intervention, long-term disease control, and quality-of-life preservation—an approach that closely aligns with the clinical needs of heart failure patients. Technological innovation and broader accessibility in heart failure treatment are therefore key to translating healthcare concepts into real-world impact.

Ventricular Assist and Life Support Product Portfolio

Starting from clinical demands in heart failure care, magAssist has developed a portfolio of ventricular assist and extracorporeal life support technologies designed to support hemodynamic stability in high-risk cardiovascular scenarios:

MoyoAssist® Extracorporeal VAD

This device is used in multiple tertiary hospitals to provide circulatory support for patients during high-risk PCI, treatment for acute heart failure, and complex cardiovascular surgeries. It is designed to maintain hemodynamic stability and can serve as a bridge to organ transplantation or cardiac function recovery.

NyokAssist® Percutaneous VAD

A collapsible, minimally invasive device intended for short-term cardiac support. It has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA).

BreathMo® Portable ECMO System

This is a fully magnetically levitated extracorporeal membrane oxygenation (ECMO) system. The design aims to improve hemocompatibility and has indications for both extracorporeal ventricular assistance and extracorporeal membrane oxygenation.

Dual-Engine Strategy: China and Global Markets

magAssist's development is driven by sustained technological innovation and interdisciplinary collaboration. Founded by Po-Lin Hsu, PhD, the company integrates engineering and clinical expertise to advance ventricular assist and life support technologies.

With a strong intellectual property foundation and active international clinical collaboration, magAssist is advancing both domestic adoption and global expansion, supporting future multicenter clinical research and overseas market entry.

Grounded in Clinical Needs, Serving Global Health

Aligned with Fortune's focus on health and longevity, magAssist continues to translate technological innovation into clinically accessible solutions. By advancing ventricular assist and life support technologies, the company aims to deliver reliable, scalable support for patients facing severe cardiovascular and cardiopulmonary conditions worldwide.